If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 6 of 6
A Phase 1, Multicenter, Single-arm, Dose-escalation Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Relapsing Forms of Multiple Sclerosis (RMS) or Pr
Objective
Dose Escalation Study of CC-97540 in RMS or PM
Protocol No
NEURO-BMS-CA061-1006
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (Nmdar) Or Anti-Leuci
Objective
Satralizumab in NMDAR or LGI1 Enchephalitis
Protocol No
NEURO-GENENTECH-CIELO
Master Protocol of Two Independent, Randomized, Double-Blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants with Relapsing Forms of Multiple Sclerosis
Objective
Master Protocol for SAR441344 to Teriflunomide in Relapsing MS
Protocol No
NEURO-SANOFI-EFC17919
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 and Ocrevus (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
Objective
ABP692 v Ocrelizumab in Relapsing-Remitting MS
Protocol No
NEURO-AMGEN-20230309
Evaluating Efficacy When Transitioning From a Current Disease Modifying Therapy DMT to Ublituximab -ENHANCE
Objective
Efficacy Transitioning from a Current DMT to Ublituximab
Protocol No
NEURO-TG-ENHANCE
A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis
Objective
Best Available Therapy vs Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis
Protocol No
NEURO-ITN-077I-BEAT-MS